Agilent Technologies (A) U.S. All Stars Conference summary

Strategic transformation and operational performance

• Ignite transformation evolved into a comprehensive operating system, driving resource allocation, innovation, and operational improvements, resulting in nearly 10-11% growth and over 100 basis points in margin expansion over two years despite tariff and tax headwinds.

• EPS improved from a 3% decline two years ago to 10% growth, with share gains and innovation fueling performance beyond end-market recovery.

• Focus for the next decade centers on autonomous labs and scientific intelligence, leveraging strong innovation investments and market positioning in pharma, chemicals, and diagnostics.

Regional and market dynamics

• China delivered double-digit growth in pharma and food, with advanced materials up high teens; long-term outlook is mid-high single-digit growth, supported by a large install base and direct technical teams.

• Asia ex-China saw 9% growth, driven by semiconductor, chemical, advanced materials, and strong momentum in India and Japan; regulatory changes in food and environmental testing are accelerating demand.

• Europe guidance was lowered due to challenging year-over-year comparisons and prudence around Middle Eastern conflict, though performance remains stable.

Product cycles and innovation

• LC replacement cycle is less than halfway complete, driving double-digit growth; GC replacement cycle is about a quarter complete, with significant room for expansion, especially in chemical and energy sectors.

• Service capability is a key differentiator, supporting share gains and customer retention; 70% of service business is on multi-year contracts, with consumables and enterprise services growing.

• R&D investments have been focused on productivity (Infinity III LC), pathology (Dako Omnis), and technical tools (9500 ICP-MS), with future emphasis on AI, autonomous labs, and software-enabled solutions.